April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Pharmacogenetics of Complement Factor H (Y402H), ARMS2(Loc387715) and Htra1 ; Treatment Response of Exudative Age-Related Macular Degeneration With Bevacizumab in Korean Population
Author Affiliations & Notes
  • H. Kang
    Ophthalmology, INHA University Hospital, Incheon Namgu, Republic of Korea
  • S. Kang
    Ophthalmology, INHA University Hospital, Incheon Namgu, Republic of Korea
  • H. Chin
    Ophthalmology, INHA University Hospital, Incheon Namgu, Republic of Korea
  • Footnotes
    Commercial Relationships  H. Kang, None; S. Kang, None; H. Chin, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 1282. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      H. Kang, S. Kang, H. Chin; Pharmacogenetics of Complement Factor H (Y402H), ARMS2(Loc387715) and Htra1 ; Treatment Response of Exudative Age-Related Macular Degeneration With Bevacizumab in Korean Population. Invest. Ophthalmol. Vis. Sci. 2010;51(13):1282.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To determine whether there is a pharmacogenetic effect of complement factor H(CFH), LOC387715 and HTRA1 genotypes on the treatment of exudative age-related macular degeneration(AMD) with bevacizumab in Korean.

Methods: : A retrospective cohort study of 75 patients diagnosed exudative AMD being treated with intravitreal bevacizumab(2.5mg) was conducted. 75 patients were followed up for more than 6 months and 54 patients were followed up for more than 1 year. All patients received three initial injection every 4weeks and were treated "as needed" based on clinical findings, optical coherence tomography and fluorescein angiography after third injection. Population who received PDT within 6month before bevacizumab injection was excluded. 39 patients who received PDT more than 6months before injection were included in the study. Genotypes were determined by allele-specific digestion of polymerase chain reaction for the CFH Y402H(rs1061170), LOC387715(rs10490924) and HTRA1(rs11200638). Treatment response was evaluated by comparing visual acuity(V/A) and Central macular thickness(CMT) of before and after initial 3time injection(immediate, 6month and 1year).

Results: : Gender, age, DM and baseline lesion size(greatest linear dimension) differences were not statistically significant in the baseline study of the each genotypes. Hypertension was statistically significant in all genotypes (CFH;P=0.036, HTRA1;P=0.028, LOC387715;P=0.016). V/A and CMT change between two groups, which received PDT and didn't, were similar and showed no significant difference statistically. V/A and CMT change of each subgroup CFH Y402H and HTRA1 gene were not statistically significant. However, 6 months visual improvement of LOC387715 was statistically significant (LogMAR, TT:from 0.959 to 0.743, GT:from 0.864 to 0.6, GG:from 1.175 to 0.988, P=0.0368).

Conclusions: : There were no positive association of the response to treatment of AMD with bevacizumab according to each genotypes of CFH, HTRA1. In LOC387715, however, high risk(TT) group showed more favorable V/A improvement in 6 months follow-up. Comparing with conventional studies, LOC387715 gene seems to be more related with AMD over CFH gene and effect the treatment response in Korean population.

Keywords: age-related macular degeneration • genetics • injection 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×